Lymphatic absorption

Lymphatic absorption refers to the physiological process by which certain substances—most notably dietary long-chain fatty acids packaged into chylomicrons—are absorbed from the small intestine into specialized lymph vessels called lacteals. These substances then enter the broader lymphatic system before eventually reaching systemic circulation via the thoracic duct. This pathway is distinct from most other nutrients, which are absorbed directly into blood capillaries and transported first through the liver. The unique features of this route have been exploited in pharmaceutical science for targeted drug delivery strategies that seek either enhanced bioavailability (by avoiding hepatic first-pass metabolism) or direct targeting of immune cells within mesenteric lymph nodes. While critical for normal fat digestion and immune surveillance, dysregulation in this system has been implicated in metabolic diseases such as obesity and serves as an important conduit for cancer metastasis from primary tumors via dissemination through regional lymph nodes[1][2][3][5]. *Note:* "Lymphatic absorption" is **not itself a molecule, protein, enzyme, transporter, or receptor**, but rather describes a physiological process involving multiple components within the intestinal mucosa and systemic lymphatics. It should not be considered a canonical therapeutic target per se; instead it represents an anatomical/functional pathway that can be leveraged by certain drugs/formulations but does not correspond to any single molecular entity amenable to direct pharmacological modulation.

Other names

Intestinal lymphatic absorptionLymphatic drug transportLymphatic uptake of lipids

Not applicable in the context of a molecular target. However: Drug formulations may increase lipophilicity to promote association with chylomicrons, facilitating entry into intestinal lacteals and subsequent lymphatic transport, thereby bypassing hepatic first-pass metabolism.